Skip to main content

Table 2 Incidence of biomarker variations and correlations with progression

From: Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

MarkerAll populationProgressionNo progression  
n = 103%n = 70n = 33pMedian delay (days)
ESR1
Mutated2221%22 (31%)0 (0%)< 0.00191 [0–282]
Non mutated8179%48 (69%)33 (100%)  
> 25% CA-15.3 increase
Yes4746%45 (64%)2 (6%)< 0.0010 [0–543]
No5654%25 (36%)31 (94%)  
> 100% CA-15.3 increase
Yes2524%23 (33%)2 (6%)0.0030 [0–91]
No7876%47 (67%)31 (94%)  
> 25% DNA increase
Yes9188%59 (84%)32 (97%)0.1182 [0–635]
No1212%11 (16%)1 (3%)  
> 100% DNA increase
Yes5553%33 (42%)22 (67%)0.192 [0–474]
No4847%37 (58%)11 (33%)  
  1. p values were determined using a chi-square test